How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights | Diaceutics

How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights

September 22nd, 2016

Steve Vitale
Peter Keeling
Ryan Keeling


To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized.

Listen to the webinar to learn:

  • 10 years of personalized medicine evidence-based insights from Diaceutics
  • The latest in data and research on PD-L1 testing, adoptions, kits and labels
  • How to prepare for targeted therapy launches
  • Laboratory mapping and optimal lab footprints based on therapy, test and target prescribers

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn